Chronotherapy using corticosteroids for multiple sclerosis relapses

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 8, 2007, Pages 886-888

  Glass Marmor, Lea ^a   Paperna, Tamar ^b   Ben Yosef, Yaara ^a   Miller, Ariel ^a,b  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISONE;

ACNE; ADULT; ARTICLE; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISABILITY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPHORIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR GROWTH; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; IMMUNE SYSTEM; INSOMNIA; LEG EDEMA; MALE; MULTIPLE SCLEROSIS; MUSCULOSKELETAL PAIN; NERVOUSNESS; OUTCOME ASSESSMENT; POLLAKISURIA; PRIORITY JOURNAL; RECURRENT DISEASE; RESTLESSNESS; SIDE EFFECT; TASTE DISCRIMINATION; TASTE DISORDER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ADULT; CHRONOTHERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 34547617700     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.104000     Document Type: Article

References (22)

1. Young MW. The tick-tock of the biological clock. Sci Am 2000;282:64-71.
2. Petrovsky N, Harrison LC. Diurnal rhythmicity of human cytokine production: a dynamic disequilibrium in T helper cell type 1/T helper cell type 2 balance? J Immunol 1997;158:5163-8.
3. Haus E, Smolensky MH. Biologic rhythms in the immune system. Chronobiol Int 1999;16:581-622.
4. Mormont MC, Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer 2003;97:155-69.
5. Moor JG. Rhythms and therapeutics of diseases of the gastrointestinal tract. In: Redfern P, eds. Chronotherapeutics. London: Pharmaceutical, 2003:127-51.
6. Auer DP, Schumann EM, Kumpfel T, et al. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;47:276-77.
7. Sandyk R. Diurnal variations in vision and relations to circadian melatonin secretion in multiple sclerosis. Int J Neurosci 1995;83:1-6.
8. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76.
9. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
10. IFNB MS Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45:1277-85.
11. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-52.
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
13. Golboiz Y, Shapiro S, Lahat N, et al. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 2001;50:443-51.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444- 52.
15. Sellebjerg F, Frederiksen JL, Nielsen PM, et al. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998;51:529-34.
16. Miller DM, Weinstock-Guttman B, Bethoux F, et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 2000;6:267-73.
17. Smolensky MH, Reinberg A. The chronotherapy of corticosteroids: practical application of chronobiologic findings to nursing. Nurs Clin North Am 1976;11:609-19.
18. Pincus DJ, Humeston TR, Martin RJ. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1997;100:771-4.
19. Ozaydin M, Dede O, Dogan A, et al. Effects of morning versus evening intake of atorvastatin on major cardiac event and restenosis rates in patients undergoing first elective percutaneous coronary intervention. Am J Cardiol 2006;97:44-7.
20. Montalban X. Do steroids have a long-term benefit? In: Thompson AJ, Polman C, Hohlfeld R, eds. Multiple sclerosis: clinical challenges and controversies. London: Martin Dunitz, 1997:155-67.
21. DeRijk RH, Eskandari F, Sternberg EM. Corticosteroid resistance in a subpopulation of multiple sclerosis patients as measured by ex vivo dexamethasone inhibition of LPS induced IL-6 production. J Neuroimmunol 2004;151:180-8.
22. van Winsen LM, Muris DF, Polman CH, et al. Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis. J Clin Endocrinol Metab 2005;90:734-40.